Athena Athena

X
[{"orgOrder":0,"company":"Island Pharmaceuticals","sponsor":"State University of New York","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Island Pharmaceuticals Granted Key Patent for ISLA-101 in the United States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Island Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            ISLA-101, has been granted by the United States Patent & Trademark Office. ISLA-101 is a drug with a very well-known safety profile, being repurposed for mosquito borne viruses.

            Lead Product(s): ISLA-101

            Therapeutic Area: Infections and Infectious Diseases Product Name: ISLA-101

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: State University of New York

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 19, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY